Qiagen NVNYSE:QGEN
- LAST PRICE45.6700
- TODAY'S CHANGE (%)0.2800 (0.6169%)
- Bid / Lots45.6800/ 2
- Ask / Lots45.7000/ 2
- Open / Previous Close45.7000 / 45.3900
- Day Range
- 52 Week Range
- Volume516,052
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QGEN |
|---|---|---|
| 09:32 ET | 20915 | 45.715 |
| 09:34 ET | 16338 | 45.74 |
| 09:36 ET | 1290 | 45.63 |
| 09:39 ET | 2977 | 45.64 |
| 09:41 ET | 700 | 45.7 |
| 09:43 ET | 200 | 45.66 |
| 09:45 ET | 357 | 45.6722 |
| 09:48 ET | 1000 | 45.64 |
| 09:50 ET | 700 | 45.6 |
| 09:52 ET | 252 | 45.58 |
| 09:54 ET | 1273 | 45.54 |
| 09:56 ET | 600 | 45.53 |
| 09:57 ET | 2100 | 45.55 |
| 09:59 ET | 934 | 45.57 |
| 10:01 ET | 600 | 45.62 |
| 10:03 ET | 1140 | 45.62 |
| 10:06 ET | 400 | 45.63 |
| 10:08 ET | 402 | 45.64 |
| 10:10 ET | 900 | 45.64 |
| 10:12 ET | 480 | 45.66 |
| 10:14 ET | 2100 | 45.64 |
| 10:15 ET | 714 | 45.63 |
| 10:17 ET | 1352 | 45.6399 |
| 10:19 ET | 300 | 45.63 |
| 10:21 ET | 712 | 45.6308 |
| 10:24 ET | 500 | 45.65 |
| 10:26 ET | 3043 | 45.56 |
| 10:28 ET | 4509 | 45.535 |
| 10:30 ET | 1754 | 45.51 |
| 10:32 ET | 1714 | 45.49 |
| 10:33 ET | 3604 | 45.53 |
| 10:35 ET | 25821 | 45.55 |
| 10:37 ET | 2892 | 45.565 |
| 10:39 ET | 2736 | 45.55 |
| 10:42 ET | 657 | 45.55 |
| 10:44 ET | 1400 | 45.55 |
| 10:46 ET | 3264 | 45.53 |
| 10:48 ET | 600 | 45.54 |
| 10:50 ET | 2520 | 45.54 |
| 10:51 ET | 2562 | 45.545 |
| 10:53 ET | 3965 | 45.54 |
| 10:55 ET | 717 | 45.5 |
| 10:57 ET | 1008 | 45.52 |
| 11:00 ET | 3814 | 45.48 |
| 11:02 ET | 1638 | 45.5299 |
| 11:04 ET | 2552 | 45.5 |
| 11:06 ET | 1788 | 45.52 |
| 11:09 ET | 2921 | 45.57 |
| 11:11 ET | 1879 | 45.6 |
| 11:13 ET | 1638 | 45.585 |
| 11:15 ET | 2003 | 45.595 |
| 11:18 ET | 320 | 45.595 |
| 11:20 ET | 200 | 45.59 |
| 11:22 ET | 1750 | 45.63 |
| 11:24 ET | 2699 | 45.62 |
| 11:26 ET | 2074 | 45.63 |
| 11:27 ET | 500 | 45.65 |
| 11:29 ET | 3025 | 45.65 |
| 11:31 ET | 5116 | 45.66 |
| 11:33 ET | 11318 | 45.65 |
| 11:36 ET | 4154 | 45.69 |
| 11:38 ET | 200 | 45.67 |
Yesterday
May 13, 2024
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results, from 2:00AM ET on Monday May 13, 2024 by Dow Jones
2:00AM ET on Monday May 13, 2024 by Dow Jones
May 7, 2024
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones
May 2, 2024
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications, from 4:06PM ET on Thursday May 02, 2024 by Dow Jones
4:06PM ET on Thursday May 02, 2024 by Dow Jones
May 1, 2024
DJ Qiagen Is Maintained at Hold by Stifel, from 9:33AM ET on Wednesday May 01, 2024 by Dow Jones
9:33AM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Qiagen NV | 10.1B | 29.9x | +12.66% |
Medpace Holdings Inc | 12.3B | 41.4x | +35.10% |
Exact Sciences Corp | 10.0B | -40.9x | --- |
United Therapeutics Corp | 12.0B | 12.9x | +8.22% |
Neurocrine Biosciences Inc | 13.9B | 38.5x | +62.04% |
Exelixis Inc | 6.1B | 32.9x | -21.77% |
Company Information
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Contact Information
- Headquarters
- Hulsterweg 82VENLO, Netherlands 5912 PL
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Supervisory Board
- Lawrence Rosen
- Chief Executive Officer, Managing Director, Member of the Executive Board
- Thierry Bernard
- Managing Director, Chief Financial Officer, Member of the Executive Board
- Roland Sackers
- Independent Member of the Supervisory Board
- Metin Colpan
- Independent Member of the Supervisory Board
- Toralf Haag
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.1B |
|---|---|
Revenue (TTM) | $2.0B |
Shares Outstanding | 221.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $1.53 |
Book Value | $17.20 |
P/E Ratio | 29.9x |
Price/Sales (TTM) | 5.1 |
Price/Cash Flow (TTM) | 18.4x |
Operating Margin | 20.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
